$37.860
+0.121 (+0.32%)Zum Schluss
Umsatzquellen von PNTG
The Pennant Group, Inc. (PNTG) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medicare, accounting for 50.9% of total sales, equivalent to $151.65M. Other significant revenue streams include Private and other and Managed care. Understanding this composition is critical for investors evaluating how PNTG navigates market cycles within the Healthcare Facilities & Services industry.
Profitabilität und Margen von PNTG
Evaluating the bottom line, The Pennant Group, Inc. maintains a gross margin of 12.91%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 6.22%, while the net margin is 3.66%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PNTG converts its operational activities into shareholder value.
PNTG im Vergleich zur Peergroup
In the context of the broader market, PNTG competes directly with industry leaders such as NUTX and GDRX. With a market capitalization of $1.28B, it holds a leading position in the sector. When comparing efficiency, PNTG's gross margin of 12.91% stands against NUTX's 67.04% and GDRX's 78.41%. Such benchmarking helps identify whether The Pennant Group, Inc. is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von Pennant Group Inc
Pennant Group has demonstrated consistent revenue growth, with Q2 2026 revenue of $298 million, up from $219 million in Q2 2025. The net income for Q2 2026 was $9.08 million, reflecting a healthy net margin of 3.66%.
Financials
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.